Rx Kickbacks: HHS Has No Legal Ground For Pursuing AWP Spread - Attorneys
Executive Summary
Government challenges of the spread between AWP and the actual sale price of a drug to a physician as a kickback is an "imaginative anti-kickback theory" with no legal precedent, attorney Michael Kendall (McDermott, Will & Emery, Boston) said June 11.
You may also be interested in...
Rx Pricing/Marketing Defense Based On "Industry Standard" Losing Viability
Drug manufacturers' claim that their pricing and marketing practices are in line with "industry standards" is not a viable defense, speakers at the Health Care Compliance Association and Food & Drug Law Institute compliance symposium said.
Rx Pricing/Marketing Defense Based On "Industry Standard" Losing Viability
Drug manufacturers' claim that their pricing and marketing practices are in line with "industry standards" is not a viable defense, speakers at the Health Care Compliance Association and Food & Drug Law Institute compliance symposium said.
Rx Sampling In "Spotlight" Of Boston Grand Jury As Part Of TAP Investigation
Pharmaceutical companies should consider how their sampling programs will look in "the very bright spotlight of a federal grand jury investigation," Boston Assistant U.S. Attorney Michael Loucks said during the Food & Drug Law Institute annual meeting April 19 in Washington, D.C.